KDR and cancer: Conversely, bleomycin (a chemotherapy drug primarily used in the treatment of certain types of cancer), OSI-930, and sorafenib (VEGFR2 inhibitors) showed higher IC50 values in high-risk patients, suggesting that these patients may resistant to these drugs (Figures 8A–F).